{"id":222,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1993-12-06","marketCap":12353.9541015625,"name":"Incyte Corp","phone":"13024986700.0","outstanding":224.08999633789062,"symbol":"INCY","website":"https://www.incyte.com/","industry":"Biotechnology"},"price":55.46875,"year":2023,"month":10,"day":21,"weekday":"Saturday","title":"The Impact of Natural Disasters on Incyte Corp's Operations and Stock Performance","date":"2023-10-21","url":"/posts/2023/10/21/INCY","content":[{"section":"Introduction","text":"Incyte Corp is a biopharmaceutical company that develops and markets innovative medicines to treat serious diseases. While the company's focus may not inherently make it susceptible to the direct impact of natural disasters, climate-related events can have indirect consequences that affect its operations and stock performance."},{"section":"Supply Chain Disruptions","text":"One potential impact of natural disasters on Incyte Corp's operations is supply chain disruptions. The company relies on a network of suppliers to obtain raw materials and components necessary for manufacturing its drugs. Severe weather events, such as hurricanes or floods, can disrupt transportation systems and cause delays in the delivery of these essential inputs. Consequently, the company may face challenges in meeting its production targets, leading to potential revenue losses and a decline in stock performance."},{"section":"Clinical Trials and Research","text":"Climate-related events can also impact Incyte Corp's clinical trials and research activities. Natural disasters may disrupt the functioning of hospitals and research facilities, hindering the company's ability to conduct trials or collect data. Additionally, extreme weather events can create uncertainties in patient recruitment and retention, affecting the progress of ongoing studies. Delays in trials or setbacks in research can have significant implications for the company's pipeline and overall stock performance."},{"section":"Public Perception and Investor Confidence","text":"In recent years, there has been an increasing recognition of the financial risks associated with climate change. Investors are paying greater attention to companies' preparedness for climate risks and their ability to adapt to a changing environment. Incyte Corp's response to climate-related events and its efforts to mitigate risks can influence public perception and investor confidence. Positive actions, such as implementing climate resilience strategies or disclosing climate-related risks, can enhance the company's reputation and attract responsible investors. Conversely, a lack of preparedness may result in negative publicity and potential stock price declines."},{"section":"Preparedness for Climate Risks","text":"Incyte Corp recognizes the importance of climate risk management and has taken steps to enhance its preparedness. The company has highlighted climate change as one of the environmental factors it considers in its risk assessment process. Moreover, Incyte Corp has engaged in various initiatives aimed at reducing its carbon footprint and promoting sustainability. By implementing energy-saving measures, the company not only contributes to mitigating climate change but also builds resilience to potential disruptions caused by extreme weather events."},{"section":"Conclusion","text":"While Incyte Corp may not directly face the same level of operational risks from natural disasters as industries like agriculture or real estate, climate-related events can still impact the company's operations and stock performance indirectly. Supply chain disruptions and interruptions in clinical trials and research are potential challenges that may arise. However, Incyte Corp's recognition of climate risks and its efforts to improve climate resilience demonstrate a proactive approach to managing these challenges. By prioritizing sustainability and preparedness, Incyte Corp strives to mitigate potential adverse effects and maintain investor confidence amidst a changing climate landscape."}],"tags":["stock","Short","Biotechnology"],"news":[{"category":"company","date":1697822160,"headline":"Incyte Corp. stock falls Friday, still outperforms market","id":123309770,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. sank 0.92% to $55.13 Friday, on what proved to be an all-around rough trading session for the stock market, with the S\u0026P 500 Index...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-falls-friday-still-outperforms-market-194e02b6-d7d16e4191c4"},{"category":"company","date":1697796240,"headline":"First Week of June 2024 Options Trading For Incyte (INCY)","id":123288981,"image":"","symbol":"INCY","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3169965273"},{"category":"company","date":1697735760,"headline":"Incyte Corp. stock underperforms Thursday when compared to competitors","id":123309771,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. shed 2.08% to $55.64 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S\u0026P 500 Index...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-thursday-when-compared-to-competitors-4bbfe9d1-415c99c722ad"},{"category":"company","date":1697649360,"headline":"Incyte Corp. stock underperforms Wednesday when compared to competitors","id":123309772,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. dropped 0.65% to $56.82 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S\u0026P 500...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-wednesday-when-compared-to-competitors-3cb8d947-7ca39fb978b5"},{"category":"company","date":1697633343,"headline":"Incyte: One Of The Most Undervalued Pharmaceuticals","id":123232066,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413597282/image_1413597282.jpg?io=getty-c-w1536","symbol":"INCY","publisher":"SeekingAlpha","summary":"Incyte stock declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Read more about INCY here.","url":"https://seekingalpha.com/article/4641563-incyte-one-of-the-most-undervalued-pharmaceuticals"},{"category":"company","date":1697616000,"headline":"Incyte to Present at Upcoming Investor Conferences","id":123243035,"image":"","symbol":"INCY","publisher":"Business Wire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=4ktvcojz8h"},{"category":"company","date":1697562900,"headline":"Incyte Corp. stock underperforms Tuesday when compared to competitors","id":123217896,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. slumped 0.76% to $57.19 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-underperforms-tuesday-when-compared-to-competitors-ac07c4d6-0501d92ec914"},{"category":"company","date":1697476500,"headline":"Incyte Corp. stock rises Monday, still underperforms market","id":123217897,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. inched 0.03% higher to $57.63 Monday, on what proved to be an all-around great trading session for the stock market, with the S\u0026P 500...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-rises-monday-still-underperforms-market-db00f440-6a7223285c1c"},{"category":"company","date":1697457600,"headline":"Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023","id":123178564,"image":"https://media.zenfs.com/en/business-wire.com/86a77932cc29da8ac375a60c2ed4fa55","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 16, 2023--Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023","url":"https://finance.yahoo.com/news/incyte-announces-data-across-oncology-120000099.html"},{"category":"company","date":1697217360,"headline":"Incyte Corp. stock outperforms competitors on strong trading day","id":123162125,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. rose 1.84% to $57.61 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-outperforms-competitors-on-strong-trading-day-ab6a00cf-5239fadb62c4"},{"category":"company","date":1697215440,"headline":"Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why","id":123147970,"image":"https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b","symbol":"INCY","publisher":"Yahoo","summary":"Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.","url":"https://finance.yahoo.com/news/incyte-incy-stock-plummets-29-164400922.html"},{"category":"company","date":1697207400,"headline":"Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis","id":123131197,"image":"https://media.zenfs.com/en/business-wire.com/ad09d5765acd655a0b5b28f34426fb6f","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 13, 2023--Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis","url":"https://finance.yahoo.com/news/incyte-announces-data-ruxolitinib-cream-143000734.html"},{"category":"company","date":1697198400,"headline":"Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)","id":123131198,"image":"https://media.zenfs.com/en/business-wire.com/9c0107625bf876059c356b61e8f4f6e2","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 13, 2023--Data from Incyte’s Povorcitinib Clinical Program to be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)","url":"https://finance.yahoo.com/news/data-incyte-povorcitinib-clinical-program-120000565.html"},{"category":"company","date":1697193000,"headline":"Incyte says study evaluating efficacy of ruxolitinib cream in children met primary endpoint","id":123139619,"image":"","symbol":"INCY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3159167837"},{"category":"company","date":1697189820,"headline":"Incyte announces new data from Phase 3 TRuE-AD3 study of ruxolitinib cream","id":123139621,"image":"","symbol":"INCY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3159101552"},{"category":"company","date":1697130960,"headline":"Incyte Corp. stock falls Thursday, underperforms market","id":123162126,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. dropped 0.68% to $56.57 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S\u0026P 500...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-falls-thursday-underperforms-market-dc6d3059-0872fd66b500"},{"category":"company","date":1697124540,"headline":"Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study","id":123118262,"image":"https://media.zenfs.com/en/zacks.com/44fc6e96ff9dff6be2f033510781bcfa","symbol":"INCY","publisher":"Yahoo","summary":"Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.","url":"https://finance.yahoo.com/news/incyte-incy-posts-upbeat-data-152900961.html"},{"category":"company","date":1697115600,"headline":"Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032","id":123104443,"image":"https://media.zenfs.com/en/globenewswire.com/7702ebea805b5988f4ca28c15b692f22","symbol":"INCY","publisher":"Yahoo","summary":"PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic","url":"https://finance.yahoo.com/news/global-car-t-cell-therapy-130000592.html"},{"category":"company","date":1697092860,"headline":"Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Fusion Pharmaceuticals (FUSN)","id":123109926,"image":"","symbol":"INCY","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3157131583"},{"category":"company","date":1697044560,"headline":"Incyte Corp. stock falls Wednesday, underperforms market","id":123107079,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. shed 0.49% to $56.96 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S\u0026P 500 Index...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-falls-wednesday-underperforms-market-456461e3-0806f590fc4f"},{"category":"company","date":1697034600,"headline":"New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients","id":123090483,"image":"https://media.zenfs.com/en/business-wire.com/0ae471e2c3dc25026c8596389a6f6556","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 11, 2023--New Long-Term Phase 3 TRuE-V Data Demonstrates Efficacy of Continued Treatment with Opzelura (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients","url":"https://finance.yahoo.com/news/long-term-data-incyte-phase-143000663.html"},{"category":"company","date":1697030100,"headline":"Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity","id":123090484,"image":"https://media.zenfs.com/en/business-wire.com/68a09291989766fd6bc2ee0dabade476","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 11, 2023--Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity","url":"https://finance.yahoo.com/news/incyte-mandy-moore-partner-empower-131500008.html"},{"category":"company","date":1697028000,"headline":"Syndax initiated Buy at Goldman Sachs citing sales ops next year","id":123083862,"image":"","symbol":"INCY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3155854655"},{"category":"company","date":1697026500,"headline":"Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo","id":123090485,"image":"https://media.zenfs.com/en/business-wire.com/cdb54d1aa303c9b17abef937682b898b","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 11, 2023--Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo","url":"https://finance.yahoo.com/news/incyte-announces-positive-52-week-121500185.html"},{"category":"company","date":1697016780,"headline":"Incyte: Data from Phase 3 TRuE-V demonstrates efficacy of Opzelura treatment","id":123083866,"image":"","symbol":"INCY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3155610915"},{"category":"company","date":1697010060,"headline":"Incyte 52-week data from study evaluating povorcitinib in vitiligo patients","id":123083871,"image":"","symbol":"INCY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3155472626"},{"category":"company","date":1697009400,"headline":"S\u0026P 500 Futures Rise in Premarket Trading; DaVita, Baxter International Lag","id":123106491,"image":"https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png","symbol":"INCY","publisher":"MarketWatch","summary":"With U.S. stock markets set to open in two hours, (TECH) was up 7.4% in pre-market trading, and (ALLY) was up 5.0%. (INCY), (ESLT), and (FRT) were all...","url":"https://www.marketwatch.com/articles/s-p-500-futures-rise-in-premarket-trading-davita-baxter-international-lag-5620b58d"},{"category":"company","date":1696970700,"headline":"Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil","id":123065789,"image":"https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea","symbol":"INCY","publisher":"Yahoo","summary":"MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto","url":"https://finance.yahoo.com/news/knight-therapeutics-announces-regulatory-submission-204500575.html"},{"category":"company","date":1696939200,"headline":"Incyte to Report Third Quarter Financial Results","id":123056965,"image":"https://media.zenfs.com/en/business-wire.com/7b87cbac4705e432f448569c3eb3aee8","symbol":"INCY","publisher":"Yahoo","summary":"WILMINGTON, Del., October 10, 2023--Incyte to Report Third Quarter Financial Results","url":"https://finance.yahoo.com/news/incyte-report-third-quarter-financial-120000102.html"},{"category":"company","date":1696909680,"headline":"Incyte brazilian affiliate submits authorization for pemigatinib to ANVISA","id":123071041,"image":"","symbol":"INCY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3154334483"},{"category":"company","date":1696871700,"headline":"Incyte Corp. stock falls Monday, underperforms market","id":123107082,"image":"https://images.mktw.net/im-220105/social","symbol":"INCY","publisher":"MarketWatch","summary":"Shares of Incyte Corp. shed 1.13% to $56.68 Monday, on what proved to be an all-around great trading session for the stock market, with the S\u0026P 500 Index...","url":"https://www.marketwatch.com/data-news/incyte-corp-stock-falls-monday-underperforms-market-52a4d890-3afa44561849"}]}